

产品名称：酮咯酸氨丁三醇峰
 产品别名：酮咯酸；Ketorolac；RS37619

生物活性:	
Description	Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC ₅₀ s of 20 nM for COX-1 and 120 nM for COX-2.
IC₅₀ & Target [1]	COX-1
	COX-2
	20 nM (IC ₅₀)
	120 nM (IC ₅₀)
In Vitro	Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC ₅₀ s of 20 nM for COX-1 and 120 nM for COX-2[1].
In Vivo	Ketorolac tromethamine (0.4%) causes nearly complete inhibition on LPS endotoxin-induced increases in FITC-dextran in the anterior chamber, and increases in aqueous PGE ₂ concentrations in the aqueous humor in rabbits[1]. Ketorolac (30 mg/kg, i.v.) rapidly reverses hyperalgesia in rats. Ketorolac also reduces carrageenan-induced hyperalgesia and paw PG production, and causes reduction in PGE ₂ levels in rats[1]. Ketorolac (4 mg/kg/day, p.o.) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats[2]. Ketorolac (60 µg/10 µL) reduces the histological changes such as ischemic cell death, including cytoplasmic eosinophilia with disintegration of cytoarchitecture and nuclear pyknosis in rats. Ketorolac also effectively reduces neuronal death and improves hindlimb motor function, and the long-term survival is similar to that in the control group[3].
References	[1]. Waterbury LD, et al. <u>Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.</u> <i>Curr Med Res Opin.</i> 2006 Jun;22(6):1133-40. [2]. Fracon RN, et al. <u>Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats.</u> <i>J Appl Oral Sci.</i> 2010 Dec;18(6):630-4. [3]. Hsieh YC, et al. <u>Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats.</u> <i>Anesth Analg.</i> 2005 Apr;100(4):1134-9.
实验参考:	
Animal Administration	Rats[2] Treated rats receive oral doses of 1 mL aqueous solution of paracetamol (80 mg/kg/rat/day), Ketorolac (4 mg/kg/day) or etoricoxib (10 mg/kg/day) administered by gavage from the day of surgery until death, 2 weeks later. Control rats receive tap water (1 mL/day by gavage). The animals are housed under climate-controlled environment (12 h light/12 h dark, 20-24°C) with free access to standard laboratory chow and tap water[2].
References	[1]. Waterbury LD, et al. <u>Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.</u> <i>Curr Med Res Opin.</i> 2006 Jun;22(6):1133-40. [2]. Fracon RN, et al. <u>Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats.</u> <i>J Appl Oral Sci.</i> 2010 Dec;18(6):630-4. [3]. Hsieh YC, et al. <u>Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats.</u> <i>Anesth Analg.</i> 2005 Apr;100(4):1134-9.